Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

NCT02098343 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.

NCT NCT02098343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02098343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Lead sponsor
Aprea Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2014
Completion date
April 30, 2019
Enrollment
247 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

platinum sensitive recurrent high-grade serous ovarian cancer with mutated p53